Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cancer vaccine development has been vigorously pursued for 40 years. Immunity to tumor antigens can be elicited by most vaccines tested, but their clinical efficacy remains modest. We argue that a concerted international effort is necessary to understand the human antitumor immune response and achieve clinically effective cancer vaccines.

Original publication

DOI

10.1126/scitranslmed.aaf0685

Type

Journal article

Journal

Science translational medicine

Publication Date

04/2016

Volume

8

Pages

334ps9 - 334ps9

Addresses

Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland.

Keywords

T-Lymphocytes, Humans, Cancer Vaccines, Antigens, Neoplasm, Immunologic Memory